Lipella Pharmaceuticals Inc.Lipella Pharmaceuticals Inc.Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc.

No trades
See on Supercharts

LIPO fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
LIPO has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company